deferoxamine has been researched along with Brain Disorders in 37 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Excerpt | Relevance | Reference |
---|---|---|
" In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 7.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 7.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
"Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 5.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
" In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 3.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 3.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
" The metal chelator deferoxamine as well as three nitroxide derivatives, differing in hydrophilicity and charge, and one hydroxylamine (a reduced nitroxide) facilitated the clinical recovery and decreased the brain edema." | 3.70 | Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. ( Bass, R; Beit-Yannai, E; Samuni, A; Shohami, E; Trembovler, V; Zhang, R, 1998) |
" It is recommended to implement a stepwise increasing desferrioxamine dosage to prevent an acute decompensation with irreversible neurological lesions." | 2.58 | [Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature]. ( Canaud, B; Dard, S; Drueke, T; Dupuis, E; Massy, ZA; Seidowsky, A, 2018) |
"Aneurysmal subarachnoid hemorrhage (SAH) affects approximately 27,000 Americans per year." | 1.36 | Iron and early brain injury after subarachnoid hemorrhage. ( Loftspring, MC, 2010) |
"Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 1.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
"Two patients with progressive dialysis encephalopathy (PDE) were subjected to serial EEG recording and neuropsychological tests in order to assess the value of the investigations as indices of the course of PDE during desferrioxamine treatment." | 1.27 | The EEG in progressive dialysis encephalopathy. The EEG and clinical indices of PDE in cases treated with desferrioxamine. (Part. II). ( Canavese, C; Luda, E; Rocca, G, 1984) |
"Five patients with dialysis encephalopathy were transferred to deionized water; all died after a variable period, 4 of progressive dementia." | 1.27 | The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. ( Bell, P; Meyers, AM; Milne, FJ; Sharf, B, 1983) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 21 (56.76) | 18.7374 |
1990's | 11 (29.73) | 18.2507 |
2000's | 2 (5.41) | 29.6817 |
2010's | 2 (5.41) | 24.3611 |
2020's | 1 (2.70) | 2.80 |
Authors | Studies |
---|---|
Zeinivand, M | 1 |
Nahavandi, A | 1 |
Zare, M | 1 |
Seidowsky, A | 1 |
Dupuis, E | 1 |
Drueke, T | 1 |
Dard, S | 1 |
Massy, ZA | 1 |
Canaud, B | 1 |
Okauchi, M | 1 |
Hua, Y | 1 |
Keep, RF | 1 |
Morgenstern, LB | 1 |
Xi, G | 1 |
Loftspring, MC | 1 |
Ackrill, P | 4 |
Ralston, AJ | 2 |
Day, JP | 4 |
Hodge, KC | 1 |
Adhemar, JP | 1 |
Laederich, J | 1 |
Jaudon, MC | 1 |
Masselot, JP | 1 |
Galli, A | 1 |
Kleinknecht, D | 1 |
Arze, RS | 1 |
Parkinson, IS | 1 |
Cartlidge, NE | 1 |
Britton, P | 1 |
Ward, MK | 1 |
Pogglitsch, H | 1 |
Petek, W | 1 |
Wawschinek, O | 1 |
Holzer, W | 1 |
Milne, FJ | 2 |
Sharf, B | 2 |
Bell, PD | 1 |
Meyers, AM | 2 |
Payton, CD | 1 |
Junor, BJ | 1 |
Fell, GS | 1 |
Pierides, AM | 1 |
Myli, MP | 1 |
Luda, E | 2 |
Canavese, C | 2 |
Rocca, G | 1 |
Bell, P | 1 |
Kambova, L | 1 |
Ionova, D | 1 |
Kirijakov, Z | 1 |
Savory, J | 2 |
Herman, MM | 1 |
Erasmus, RT | 1 |
Boyd, JC | 1 |
Wills, MR | 1 |
Boelaert, JR | 1 |
de Locht, M | 1 |
Olivero, JJ | 1 |
Lan, J | 1 |
Jiang, DH | 1 |
Zhang, R | 1 |
Shohami, E | 1 |
Beit-Yannai, E | 1 |
Bass, R | 1 |
Trembovler, V | 1 |
Samuni, A | 1 |
Tjalkens, RB | 1 |
Ewing, MM | 1 |
Philbert, MA | 1 |
Ammon, A | 1 |
Rumpf, KW | 1 |
Hommerich, CP | 1 |
Behrens-Baumann, W | 1 |
Rüchel, R | 1 |
Anand, VK | 1 |
Alemar, G | 1 |
Griswold, JA | 1 |
Wens, R | 1 |
Devriendt, J | 1 |
Collart, F | 1 |
Dratwa, M | 1 |
Bisschop, P | 1 |
Telerman-Toppet, N | 1 |
Douat, N | 1 |
Ellenberg, R | 1 |
King, AL | 1 |
Sica, DA | 1 |
Posner, M | 1 |
Lillevang, ST | 1 |
Pedersen, FB | 1 |
Arizono, K | 1 |
Fukui, H | 1 |
Miura, H | 1 |
Hayano, K | 1 |
Otsuka, Y | 1 |
Tajiri, M | 1 |
Rovelli, E | 1 |
Luciani, L | 1 |
Pagani, C | 1 |
Albonico, C | 1 |
Colleoni, N | 1 |
D'Amico, G | 1 |
Coburn, JW | 1 |
Norris, KC | 1 |
Sherrard, DJ | 1 |
Bia, M | 1 |
Llach, F | 1 |
Alfrey, AC | 1 |
Slatopolsky, E | 1 |
Starkstein, S | 1 |
Berthier, M | 1 |
Nogués, M | 1 |
Leiguarda, R | 1 |
Lewis, M | 1 |
Lesniak, S | 1 |
Mudde, AH | 1 |
Roodvoets, AP | 1 |
Van Groningen, K | 1 |
Dooling, EC | 1 |
Schoene, WC | 1 |
Richardson, EP | 1 |
Gallyas, F | 1 |
Környey, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 3 |
Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 1 |
Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 0 |
Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 9 |
Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 6 |
Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 0 |
Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 6 |
Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 12 |
Normal Saline | 14 |
4 reviews available for deferoxamine and Brain Disorders
Article | Year |
---|---|
[Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature].
Topics: Aluminum; Brain Diseases; Deferoxamine; Electrocardiography; Humans; Kidney Failure, Chronic; Male; | 2018 |
The use of desferrioximine in dialysis-associated aluminium disease.
Topics: Aluminum; Anemia; Bone Diseases; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Rena | 1993 |
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease | 1997 |
Intracranial complications of mucormycosis: an experimental model and clinical review.
Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete | 1992 |
33 other studies available for deferoxamine and Brain Disorders
Article | Year |
---|---|
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, | 2020 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Iron and early brain injury after subarachnoid hemorrhage.
Topics: Animals; Brain Diseases; Deferoxamine; DNA Damage; Humans; Iron; Iron Chelating Agents; Oxidative St | 2010 |
Successful removal of aluminium from patient with dialysis encephalopathy.
Topics: Adult; Aluminum; Brain; Brain Diseases; Deferoxamine; Hemodialysis, Home; Humans; Male | 1980 |
Removal of aluminium from patients with dialysis encephalopathy.
Topics: Adult; Aged; Aluminum; Blood; Brain Diseases; Deferoxamine; Humans; Renal Dialysis; Ultrafiltration | 1980 |
Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment.
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Male; Renal Dialysis; Water Supply | 1981 |
Treatment of early stages of dialysis encephalopathy by aluminium depletion.
Topics: Aluminum; Apraxias; Brain Diseases; Deferoxamine; Dysarthria; Humans; Male; Renal Dialysis | 1981 |
Low aluminium water, desferrioxamine, and dialysis encephalopathy.
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Renal Dialysis; Water Supply | 1982 |
Successful treatment of aluminium encephalopathy by intraperitoneal desferrioxamine.
Topics: Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Injections, Intraperitoneal; Middle Aged; Pe | 1984 |
Therapy of aluminum overload (I).
Topics: Adult; Aged; Aluminum; Bone and Bones; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, | 1984 |
The EEG in progressive dialysis encephalopathy. The EEG and clinical indices of PDE in cases treated with desferrioxamine. (Part. II).
Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Humans; Middle Aged; Neuropsychologi | 1984 |
EEG study on progressive dialytic encephalopathy in treatment with desferrioxamine.
Topics: Brain Diseases; Deferoxamine; Electroencephalography; Humans; Renal Dialysis | 1983 |
The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
Topics: Adult; Aged; Aluminum; Bone Diseases; Brain Diseases; Deferoxamine; Dementia; Electroencephalography | 1983 |
Therapy of aluminium overload (II).
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Renal Dialysi | 1984 |
Aluminium overload influences cognitive function in patients on dialysis.
Topics: Adult; Aluminum; Brain Diseases; Chelating Agents; Cognition; Deferoxamine; Female; Humans; Male; Mi | 1994 |
Partial reversal of aluminium-induced neurofibrillary degeneration by desferrioxamine in adult male rabbits.
Topics: Aluminum Compounds; Animals; Brain Diseases; Deferoxamine; Histocytochemistry; Injections, Intravent | 1994 |
Side-effects of desferrioxamine in dialysis patients.
Topics: Bacterial Infections; Brain Diseases; Deferoxamine; Eye; Hearing Loss, Sensorineural; Humans; Iron; | 1993 |
Hemoptysis and altered sensorium in a hemodialysis patient.
Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Hemoptysis; Humans; Kidney Failure, Chro | 1993 |
Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain Diseases; Brain Edema; Deferoxamine; Head Injuries | 1998 |
Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy.
Topics: Adenosine Triphosphate; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Cal | 2000 |
[Rhinocerebral mucormycosis during deferoxamine therapy].
Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human | 1992 |
Rhinocerebral mucormycosis in haemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor.
Topics: Amphotericin B; Brain Diseases; Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Nasal Mucosa; | 1991 |
Cerebrospinal fluid aluminum levels following deferoxamine.
Topics: Adult; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Kidney Trans | 1990 |
Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Di | 1989 |
[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine].
Topics: Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Rena | 1989 |
Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Female; Humans; Male; Middle Aged; N | 1988 |
Toxic effects of aluminum in end-stage renal disease: discussion of a case.
Topics: Aluminum; Bone Diseases, Metabolic; Brain Diseases; Deferoxamine; Female; Hemodialysis, Home; Humans | 1988 |
Role of desferrioxamine in the treatment of dialysis encephalopathy.
Topics: Adult; Aged; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; | 1986 |
[Treatment of dialysis encephalopathy with deferoxamine].
Topics: Adult; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Electroencephalography; Humans; Male; Renal | 1986 |
Deferoxamine use in aluminum toxicity.
Topics: Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Middle Aged; Renal Dialysis | 1986 |
Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
Topics: Aluminum Hydroxide; Brain Diseases; Deferoxamine; Female; Humans; Hypercalcemia; Male; Middle Aged; | 1985 |
Hallervorden-Spatz syndrome.
Topics: Adult; Amantadine; Autopsy; Brain; Brain Diseases; Cerebral Cortex; Deferoxamine; Electroencephalogr | 1974 |
[A further contribution to the knowledge of the Hallervorden-Spatz disease].
Topics: Adolescent; Brain Diseases; Deferoxamine; Globus Pallidus; Humans; Iron; Iron Isotopes; Male; Molecu | 1968 |